Healthcare Industry News: Beckman Coulter
News Release - March 6, 2006
Beckman Coulter Announces FDA Clearance of the UniCel(R) DxC 600i Chemistry-Immunoassay SystemFULLERTON, Calif., March 6 (HSMN NewsFeed) -- Beckman Coulter, Inc. (NYSE: BEC ) announced today that its newest chemistry-immunoassay workstation -- the UniCel DxC 600i Synchron® Access® clinical system -- has been cleared by the U.S. Food and Drug Administration.
The DxC 600i continues the company's strategy of delivering standardized product lines with large onboard test menus for greater workstation consolidation. With an on-board capacity of 89 reagents, the second generation workcell offers a menu of more than 150 different tests, ranging from cardiac and tumor markers to tests for renal function, diabetes and more.
The DxC 600i, available for shipment in mid-2006, enables clinical laboratories to perform both chemistry and immunoassay testing simultaneously from a single point of sample entry.
"Workcells are often the first step in automating a clinical diagnostics laboratory, bringing valuable workflow benefits and efficiencies. This latest addition to the UniCel product family helps labs obtain the perfect blend of chemistry and immunoassay testing with exceptional productivity," said Jeff McHugh, group vice president of lab systems and routine testing for Beckman Coulter's diagnostics division. "In line with our simplify, automate and innovate focus, we've carefully designed this system to offer labs tremendous flexibility to meet their operational needs, including workstation consolidation, increased reliability, greater productivity and lower costs."
The DxC 600i will be the only system of its kind with closed-tube sampling (CTS) and closed-tube aliquotting (CTA) capabilities. By eliminating the de-capping and re-capping steps in the laboratory process, these features help increase lab efficiency and enhance operator safety. The system offers a throughput up to 990 chemistry tests per hour and up to 100 immunoassay tests per hour.
Beckman Coulter, Inc. is a leading manufacturer of biomedical testing instrument systems, tests and supplies that simplify and automate laboratory processes. Spanning the biomedical testing continuum -- from pioneering medical research and clinical trials to laboratory diagnostics and point-of-care testing -- Beckman Coulter's 200,000 installed systems provide essential biomedical information to enhance health care around the world. The company, based in Fullerton, Calif., reported 2005 annual sales of $2.44 billion with 71.5 percent of this amount generated by recurring revenue from supplies, test kits, services and operating-type lease payments. For more information, visit www.beckmancoulter.com or call (800) 352-3433.
Source: Beckman Coulter
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.